Evotec SE (EVO)
USD 3.58
(-0.56%)
USD 3.58
(-0.56%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 24.12 Million EUR | -107.61% |
| 2022 | -57.61 Million EUR | -0.82% |
| 2021 | 94.92 Million EUR | -4.1% |
| 2020 | 98.98 Million EUR | -18.63% |
| 2019 | 112.93 Million EUR | 28.36% |
| 2018 | 105.88 Million EUR | 62.42% |
| 2017 | 58.35 Million EUR | 18.76% |
| 2016 | 46.36 Million EUR | 381.46% |
| 2015 | 26.15 Million EUR | -8.77% |
| 2014 | 4.99 Million EUR | -17.82% |
| 2013 | -12.61 Million EUR | 36.87% |
| 2012 | 5.66 Million EUR | -30.35% |
| 2011 | 13.32 Million EUR | 54.18% |
| 2010 | 10.24 Million EUR | 154.2% |
| 2009 | -39.6 Million EUR | 65.5% |
| 2008 | -70 Million EUR | -37.29% |
| 2007 | -5.88 Million EUR | -82.9% |
| 2006 | -22.15 Million EUR | -3187.67% |
| 2005 | -18.43 Million EUR | 97.87% |
| 2004 | -28.12 Million EUR | 9.64% |
| 2003 | -31.12 Million EUR | -30.15% |
| 2002 | -23.91 Million EUR | -87.72% |
| 2001 | -12.73 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -32.86 Million EUR | -546.93% |
| 2024 Q1 | -15.94 Million EUR | -36.3% |
| 2023 Q1 | -1.21 Million EUR | -103.42% |
| 2023 Q2 | -25.96 Million EUR | -2029.78% |
| 2023 Q4 | -22.88 Million EUR | -134.7% |
| 2023 FY | - EUR | -107.61% |
| 2023 Q3 | -9.75 Million EUR | 62.44% |
| 2022 Q3 | -14.16 Million EUR | -117.89% |
| 2022 Q1 | 60.31 Million EUR | -76.61% |
| 2022 Q2 | -6.5 Million EUR | -110.78% |
| 2022 Q4 | 35.65 Million EUR | 351.68% |
| 2022 FY | - EUR | -0.82% |
| 2021 FY | - EUR | -4.1% |
| 2021 Q2 | -66.89 Million EUR | -229.19% |
| 2021 Q1 | 51.77 Million EUR | 978.48% |
| 2021 Q3 | -114.53 Million EUR | -71.23% |
| 2021 Q4 | 257.85 Million EUR | 325.13% |
| 2020 FY | - EUR | -18.63% |
| 2020 Q4 | 4.8 Million EUR | -74.74% |
| 2020 Q3 | 19 Million EUR | 7820.0% |
| 2020 Q2 | 240 Thousand EUR | -98.6% |
| 2020 Q1 | 17.17 Million EUR | -7.71% |
| 2019 Q1 | 17.99 Million EUR | 932.13% |
| 2019 Q4 | 18.6 Million EUR | -12.9% |
| 2019 Q3 | 21.36 Million EUR | 43.48% |
| 2019 Q2 | 14.88 Million EUR | -17.24% |
| 2019 FY | - EUR | 28.36% |
| 2018 Q2 | 18.7 Million EUR | 212.86% |
| 2018 Q4 | 1.74 Million EUR | -95.28% |
| 2018 FY | - EUR | 62.42% |
| 2018 Q1 | 5.98 Million EUR | -44.16% |
| 2018 Q3 | 36.92 Million EUR | 97.38% |
| 2017 Q3 | 8.34 Million EUR | -2.72% |
| 2017 FY | - EUR | 18.76% |
| 2017 Q4 | 10.71 Million EUR | 28.31% |
| 2017 Q2 | 8.58 Million EUR | -13.76% |
| 2017 Q1 | 9.94 Million EUR | -35.0% |
| 2016 Q2 | 5.59 Million EUR | 29.04% |
| 2016 Q3 | 12 Million EUR | 114.51% |
| 2016 Q4 | 15.3 Million EUR | 27.54% |
| 2016 FY | - EUR | 381.46% |
| 2016 Q1 | 4.33 Million EUR | 130.88% |
| 2015 Q2 | 17.26 Million EUR | 817.71% |
| 2015 Q4 | -14.04 Million EUR | -4942.07% |
| 2015 FY | - EUR | -8.77% |
| 2015 Q1 | -2.4 Million EUR | -179.77% |
| 2015 Q3 | 290 Thousand EUR | -98.32% |
| 2014 Q2 | 418 Thousand EUR | 116.25% |
| 2014 Q4 | 3.01 Million EUR | -29.02% |
| 2014 FY | - EUR | -17.82% |
| 2014 Q1 | -2.57 Million EUR | -132.92% |
| 2014 Q3 | 4.24 Million EUR | 916.51% |
| 2013 Q3 | 2.44 Million EUR | 385.05% |
| 2013 Q2 | -856 Thousand EUR | 50.43% |
| 2013 Q1 | -1.72 Million EUR | -12.51% |
| 2013 FY | - EUR | 36.87% |
| 2013 Q4 | 7.81 Million EUR | 220.16% |
| 2012 Q1 | -949 Thousand EUR | 32.6% |
| 2012 Q3 | 1.92 Million EUR | -52.44% |
| 2012 Q4 | -1.53 Million EUR | -179.57% |
| 2012 FY | - EUR | -30.35% |
| 2012 Q2 | 4.05 Million EUR | 527.4% |
| 2011 Q3 | 8.11 Million EUR | 261.03% |
| 2011 Q1 | 418 Thousand EUR | -87.87% |
| 2011 Q4 | -1.4 Million EUR | -117.35% |
| 2011 FY | - EUR | 54.18% |
| 2011 Q2 | 2.24 Million EUR | 437.8% |
| 2010 Q3 | 983 Thousand EUR | -12.78% |
| 2010 Q1 | -1.13 Million EUR | -126.19% |
| 2010 FY | - EUR | 154.2% |
| 2010 Q2 | 1.12 Million EUR | 199.73% |
| 2010 Q4 | 3.44 Million EUR | 250.56% |
| 2009 Q2 | -5.71 Million EUR | 58.26% |
| 2009 Q3 | -3.14 Million EUR | 44.94% |
| 2009 Q4 | 4.31 Million EUR | 237.17% |
| 2009 FY | - EUR | 65.5% |
| 2009 Q1 | -13.68 Million EUR | 39.19% |
| 2008 Q4 | -22.5 Million EUR | -215.49% |
| 2008 FY | - EUR | -37.29% |
| 2008 Q3 | -7.13 Million EUR | 36.04% |
| 2008 Q2 | -11.15 Million EUR | 16.38% |
| 2008 Q1 | -13.33 Million EUR | -401.27% |
| 2007 Q4 | 4.42 Million EUR | 140.0% |
| 2007 Q3 | -11.06 Million EUR | -65.72% |
| 2007 Q2 | -6.67 Million EUR | 0.0% |
| 2007 Q1 | - EUR | 100.0% |
| 2007 FY | - EUR | -82.9% |
| 2006 Q3 | -5.42 Million EUR | -29.39% |
| 2006 FY | - EUR | -3187.67% |
| 2006 Q4 | -1.84 Million EUR | 65.97% |
| 2006 Q1 | -5.52 Million EUR | -20.11% |
| 2006 Q2 | -4.19 Million EUR | 24.11% |
| 2005 Q4 | -4.6 Million EUR | 0.0% |
| 2005 Q1 | -7.12 Million EUR | -33.72% |
| 2005 Q2 | -7.6 Million EUR | -6.69% |
| 2005 Q3 | - EUR | 100.0% |
| 2005 FY | - EUR | 97.87% |
| 2004 Q2 | -7.54 Million EUR | -16.84% |
| 2004 FY | - EUR | 9.64% |
| 2004 Q1 | -6.46 Million EUR | -1.54% |
| 2004 Q3 | - EUR | 100.0% |
| 2004 Q4 | -5.32 Million EUR | 0.0% |
| 2003 Q1 | - EUR | 0.0% |
| 2003 Q3 | - EUR | 0.0% |
| 2003 Q2 | - EUR | 0.0% |
| 2003 FY | - EUR | -30.15% |
| 2003 Q4 | - EUR | -18.91% |
| 2002 FY | - EUR | -87.72% |
| 2001 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Journey Medical Corporation | 1.92 Million USD | -1155.856% |
| Safety Shot Inc | -12.18 Million USD | 297.986% |
| Bright Green Corporation | - USD | -Infinity% |
| Alvotech | -484.86 Million USD | 104.976% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | -1941.032% |
| Cosmos Health Inc. | -17.06 Million USD | 241.398% |
| Dynavax Technologies Corporation | 9.66 Million USD | -149.586% |
| Embecta Corp. | 245.4 Million USD | 90.169% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 116.072% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 115.187% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 85.19% |
| PainReform Ltd. | -9.56 Million USD | 352.116% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 730.815% |
| SCYNEXIS, Inc. | 73.47 Million USD | 67.167% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | 1126.155% |
| Alpha Teknova, Inc. | -25.53 Million USD | 194.463% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 77.932% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 92.176% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 730.815% |
| Procaps Group, S.A. | 104.02 Million USD | 76.809% |
| Theratechnologies Inc. | -10.31 Million USD | 333.933% |
| Harrow Health, Inc. | 9.72 Million USD | -148.123% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | 633.149% |
| Biofrontera Inc. | -18.45 Million USD | 230.738% |
| DURECT Corporation | -24.68 Million USD | 197.735% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 75.448% |
| Cronos Group Inc. | -72.14 Million USD | 133.438% |
| OptiNose, Inc. | -15.55 Million USD | 255.115% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 102.608% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 166.862% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 8.152% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 33.044% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | 715.064% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | 3493.824% |
| Radius Health, Inc. | 38.31 Million USD | 37.027% |
| Universe Pharmaceuticals INC | -3.21 Million USD | 850.373% |
| ProPhase Labs, Inc. | -14.82 Million USD | 262.71% |
| Phibro Animal Health Corporation | 84.6 Million USD | 71.486% |
| Procaps Group S.A. | 104.02 Million USD | 76.809% |
| TherapeuticsMD, Inc. | -8.4 Million USD | 387.168% |
| Viatris Inc. | 3.51 Billion USD | 99.314% |
| Rockwell Medical, Inc. | -4.69 Million USD | 613.954% |
| Aytu BioPharma, Inc. | -1.01 Million USD | 2483.893% |
| SIGA Technologies, Inc. | 84.15 Million USD | 71.334% |
| Tilray Brands, Inc. | -72.84 Million USD | 133.119% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | -2871.059% |
| Shineco, Inc. | -26.55 Million USD | 190.853% |
| PetIQ, Inc. | 81.48 Million USD | 70.394% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | 766.873% |
| Incannex Healthcare Limited | -18.5 Million USD | 230.377% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 94.202% |
| Alimera Sciences, Inc. | 7.27 Million USD | -231.57% |
| Silver Spike Investment Corp. | 7.34 Million USD | -228.674% |
| Assertio Holdings, Inc. | -222.44 Million USD | 110.845% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | 704.538% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | 672.786% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | 243.567% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 220.44% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 116.178% |
| Hempacco Co., Inc. | -12.77 Million USD | 288.871% |
| Talphera, Inc. | -9.84 Million USD | 345.123% |
| Alvotech | -484.86 Million USD | 104.976% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | 68.872% |
| Lantheus Holdings, Inc. | 491 Million USD | 95.087% |
| Currenc Group, Inc. | -1.9 Million USD | 1369.353% |
| Kamada Ltd. | 21.53 Million USD | -12.032% |
| Indivior PLC | 66 Million USD | 63.447% |
| Evoke Pharma, Inc. | -7.29 Million USD | 430.829% |
| Flora Growth Corp. | -45.87 Million USD | 152.594% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 220.44% |
| Evolus, Inc. | -41.81 Million USD | 157.702% |
| HUTCHMED (China) Limited | 25.52 Million USD | 5.496% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 90.009% |
| Akanda Corp. | -27.73 Million USD | 186.982% |